Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions

AIDS

Volumn 16, Issue 6, 2002, Pages 895-899

  Martinez Picado, Javier ^a   Morales Lopetegi, Kristina ^a   Wrin, Terri ^a   Prado, Julia G ^a   Frost, Simon D W ^a   Petropoulos, Christos J ^a   Clotet, Bonaventura ^a   Ruiz, Lidia ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Antiviral drug resistance; HIV 1; Structured treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT PLANNING; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PHENOTYPE; RNA, VIRAL; VIRAL LOAD;

EID: 0037066371     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200204120-00009     Document Type: Article

References (24)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Residual HIV-1 infection during antiretroviral therapy: The challenge of viral persistence
3. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
4. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
5. Structured treatment interruption in chronically HIV-1 infected patients after longterm viral suppression
6. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection
7. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
8. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
9. Viral dynamics during structured therapy interruptions of chronic human immunodeficiency virus type 1 infection
10. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
11. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
12. Drug resistance is associated with impaired protease and reverse transcriptase function and reduced replication capacity: Characterization of recombinant viruses derived from 200 HIV-1 infected patients
13. Estimating relative fitness in viral competition experiments
14. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection
15. Viral dynamics in human immunodeficiency virus type I infection
16. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
17. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: A comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val
18. Evolution of lamivudine resistance in human immunodeficiency virus type 1-1nfected individuals: The relative roles of drift and selection
19. Natural variation of replication capacity measurements in drug naive/susceptible HIV-1
20. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1
21. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters
22. HIV evolution during repeated supervised treatment interruptions following early antiretroviral treatment of acute infection
23. Supervised treatment interruption (STI) following d4T/ddI/nevirapine initiated within 6 months of HIV seroconversion